首页 / 词典 / good

dlbcl

  • 网络弥漫性大B细胞淋巴瘤
dlbcldlbcl
  1. Relapse and refractory on DLBCL patients is true a huge challenge for us .

    难治复发是DLBCL患者治疗面临的一项巨大挑战。

  2. Alterations of some genes and chromosomes can analyze DLBCL heterogeneity as well .

    通过基因与染色体改变也可以建立判断弥漫大B细胞淋巴瘤异质性的模型。

  3. Diffuse large B-cell lymphoma ( DLBCL ) is a highly heterogeneous disease .

    弥漫大B细胞淋巴瘤是一种高度异质性疾病。

  4. RESULTS : Six of the 60 DLBCL were bcl-2 / IgH positive by conventional PCR method .

    结果:经常规法扩增bcl-2/IgH,有6/60例DLBCLbcl-2/IgH阳性;

  5. Whether E2F1 can be used as a germinal center B cell DLBCL marker was also discussed .

    同时对转录因子E2F1作为一种新的生发中心B细胞型DLBCL的判断指标的可行性进行探讨。

  6. DLBCL cells developed well and passed stably . The shape of cell is round or ellipse . 2 .

    结果:1.复苏的DLBCL细胞生长良好,传代稳定,细胞呈圆形。

  7. The two molecules correlated somewhat with some clinicopathological features , but not with survival of DLBCL .

    两者的表达对DLBCL的临床病理特征有一定影响,但与DLBCL患者的生存状况无明显相关。

  8. CD10 / BCL-6 expression pattern may be helpful in identifying main variants of DLBCL .

    CD10/bCL-6表达在识别变型中有重要意义。

  9. Detection and Significance of Chromosome Abnormalities Where Bcl-2 and Bcl-6 Genes Locating in DLBCL

    弥漫性大B细胞淋巴瘤bcl-2、bcl-6基因所在染色体区域异常的检测及意义

  10. The DLBCL cells are reanimated , observe the proliferative status and morphological characteristic . 2 .

    方法:1.DLBCL细胞的复苏与培养,观察细胞形态,了解生长情况和特性。

  11. Analyze the effect of different dosage and different time on the cell cycle and cell apoptosis of DLBCL cell by FCM . Results : 1 .

    应用流式细胞仪,分析不同剂量和照射后不同时间对DLBCL细胞的细胞周期和细胞凋亡影响。

  12. Its incidence increased gradually in recent years . Diffuse Large B Cell Lymphoma ( DLBCL ) of NHL happened mostly in china .

    近年来其发病率逐渐上升,我国NHL中以弥漫大B细胞淋巴瘤(DiffuselargeBcelllymphoma,DLBCL)最为多见。

  13. Methods From 1997 to 2000 , 94 DLBCL patients were studied on the expression of survivin and caspase-3 detected by immunohistochemical stain .

    方法收集1997年至2000年间初治弥漫大B细胞淋巴瘤94例,用免疫组化SP法检测其survivin、caspase-3表达情况。

  14. The survival status of stage ⅰ E patient in both MALT lymphoma and extranodal DLBCL groups was better than patients of higher stages .

    MALT淋巴瘤复发率低于结外DLBCL,而病人的5年生存率明显高于结外DLBCL。两种淋巴瘤的ⅠE期病人的存活情况较ⅠE期以上的病人好;

  15. DLBCL was diagnosed through biopsy of cervical lymph node . It may be related to posttransplant lymphoproliferative disorder .

    患者曾行肾移植术,颈部淋巴结活检后确诊为弥漫大B细胞淋巴瘤,考虑与移植后淋巴细胞增殖性疾病继发有关。

  16. Objective : To investigate the diagnosis and mechanism of bone lymphoma ( diffuse large B-cell lymphoma , DLBCL ) with secondary hyperparathyroidism .

    目的:探讨骨源性非霍奇金淋巴瘤(NHL)(弥漫型大B细胞性)伴继发性甲状旁腺机能亢进的诊断及机制。

  17. OBJECTIVE To evaluate the therapeutic effects and side - effects of Rituximab on diffuse large B cell non - Hodgkin lymphoma ( DLBCL ) .

    目的评价美罗华治疗弥漫型大B细胞性非何杰金氏淋巴瘤DLBCL的临床效果及不良反应。

  18. DLBCL is one of most common entity in NHL , its morphology , immunophenotype , genetics and clinical presentation have obvious heterogeneity .

    DLBCL是NHL中最常见的一种类型,在组织形态学、遗传学、免疫表型和临床特征上都具有明显异质性。

  19. The expression rate of Bcl-2 and NF - κ B / p65 proteins in DLBCL have relation with clinical staging , effect and prognosis .

    Bcl-2与NF-κB/p65蛋白在DLBCL中的表达与临床分期、疗效及预后有关。

  20. The 5-year overall survival of gastric DLBCL accompanying MALT lymphomas was 38.5 % ( 5 / 13 ) .

    后者的总体5年生存率为38.5%(5/13)。

  21. Objective To evaluate the efficacy and toxicity of combination of Rituximab and CHOP regimen in diffuse large B-cell lymphoma ( DLBCL ) .

    目的研究利妥昔单抗联合CHOP方案治疗弥漫大B细胞型淋巴瘤的疗效和不良反应。

  22. Objective This study is to analyze the clinical characteristics of nodal , extranodal and Waldeyer 's ring diffuse large B-cell lymphoma ( DLBCL ) .

    目的回顾性分析不同原发部位(韦氏环、结内与结外)弥漫性大B细胞淋巴瘤(DLBCL)的临床特征和预后。

  23. Cases of diffuse large B-cell lymphoma ( DLBCL ) mainly expressed CD19 , CD20 , CD10 , and HLA-DR ;

    4例弥漫大B细胞性淋巴瘤主要表达CD19、CD20、CD10和HLA-DR。

  24. This review summarizes the morphological , immunophenotypic , cytogenetic and molecular genetic features of DLBCL relevant to the precise prognostic previsions .

    作者综述DLBCL的形态学、免疫组化、分子生物学特点及与预后的关系。

  25. In pediatric and young patient populations , the most common subtypes were LBL , DLBCL and Burkitt ′ s lymphoma .

    青少年中最常见为LBL、DLBCL及Burkitt淋巴瘤。

  26. By using the hemi-nested PCR for the second round amplification , 5 of DLBCL were positive , but all of the fresh tonsil tissues were negative .

    进行第2次半巢式PCR时仅在DLBCL中发现5例阳性,新鲜扁桃体组织均阴性。

  27. Objective To observe the mutation of 5 ′ noncoding region of bcl-6 gene in diffuse large B cell lymphoma ( DLBCL ) and its effect on lymphoma pathogenesis .

    目的观察中国人弥漫性大B细胞淋巴瘤(DLBCL)中bcl6基因5′非编码区的突变情况,并探讨其作用。

  28. DLBCL clinical manifestation show certain aggressive , although most DLBCL patients react to the traditional combination chemotherapy such as CHOP , but the really cure patients are less than half .

    DLBCL(?)临床表现具有一定的侵袭性,尽管大多数DLBCL患者对传统的CHOP方案联合化疗敏感,但真正能治愈的患者不到一半。

  29. Objective To investigate the characteristics of bcl-6 mutation , rearrangement and protein expression in Chinese diffuse large B cell lymphoma ( DLBCL ) populations , and to explore their clinical values .

    目的:观察中国人弥漫大B细胞性淋巴瘤(DLBCL)中bcl-6基因突变、基因重排及蛋白表达的特征,探讨其存DLBCL发生中的作用及其临床应用价值。

  30. The international prognostic index ( IPI ) is a standard approach to assess prognosis in DLBCL . However , the survival is different in patients with identical IPI score .

    国际预后指数(IPI)对DLBCL患者的预后有很好的预测价值,但相同IPI分值患者治疗后生存期情况并不一致。